AzTrials
AzTrials

Inflammatory Bowel DiseasesCONNECT-IBDNCT02539368

Post-Marketing Use Of CT-P13 (Infliximab) For Standard Of Care Treatment Of Inflammatory Bowel Disease

An observational study of Inflammatory Bowel Diseases and Ulcerative Colitis, run by Pfizer at 140 sites in 13 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This is a post-marketing observational study of patients with Inflammatory Bowel Disease (specifically, Crohn's disease or Ulcerative Colitis) who have been prescribed CT-P13 (infliximab) or Remicade (infliximab) for treatment. Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
CT-P13 and Remicade
How many people
2,565 participants
Where
140 sitesin 13 countries
Study dates
22 Apr 2015to 31 Oct 2018
Phase
Observational
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: The target study population will include patients with CD or UC, who are being treated, or initiating treatment, with CT-P13 or Remicade at the time of study enrolment. This would include the following treatment subgroups: * Biologic-naïve patients initiating CT-P13 (or Remicade); * Patients currently being treated with CT-P13 (or Remicade); * Patients who are considered stable by the Investigator under Remicade therapy for CD or UC, who switch to CT-P13; * Patients switching to CT-P13 or Remicade from an alternative biologic therapy (e.g. adalimumab) due to non-responsiveness to or intolerance; * Patients re-initiating CT-P13 or Remicade after having successfully completed and exited a previous course of infliximab therapy in the past. * Patients with fistulating disease or stomas and those receiving combination therapy will be included.

Who may be able to join

  • At least 12 years of age at the time of initial confirmed diagnosis of CD or UC and at least 18 years of age at the time of enrolment to the study.
  • Patients who are prescribed CT-P13 or Remicade for the treatment of CD or UC prescribed according to the corresponding summary of product characteristics (SmPC) as determined by the Investigator. Patients with stomas or surgery/pouch will be included.

Who cannot join

  • Any reported contraindications for CT-P13 or Remicade, according to the SmPC.
  • Known hypersensitivity (including severe, acute infusion reactions) to infliximab, its excipients or other murine proteins, at the time of enrolment.
  • Prior history of failure to respond to Remicade or CT-P13.

Trial locations and contacts

140 sites in 13 countries.

140 sites in 13 countries

France30 sites
  • CHU Amiens

    Amiens, 80054

  • CHU Angers

    Angers, 49933

  • CHRU de Besancon

    Besançon, 25030

  • Centre Hospitalier Universitaire

    Caen, 14033

  • Clinique de Bercy

    Charenton, 94220

  • CHU Clermontferrand

    Clermont-Ferrand, 63003

  • Hopital Beaujon

    Clichy, 92110

  • Hôpital Louis Mourier

    Colombes, 92700

  • CHU de Grenoble

    Grenoble, 38043

  • CHRU

    Lille, 59000

  • Hopital Edouard Herriot Pav H

    Lyon, 69003

  • Hopital Europeen

    Marseille, 13003

  • Hopital Nord

    Marseille, 13015

  • CHU

    Montpellier, 34295

  • CHU Nimes

    Nîmes, 30029/Cedex 9

  • Hôpital Saint-Antoine, AP-HP, Universite Pierre-et-Marie-Curie

    Paris, 75012

  • Hopital Cochin

    Paris, 75014

  • Institut Montsouris

    Paris, 75014

  • Hôpital Européen Georges Pompidou

    Paris, 75015

  • Hopital St Louis

    Paris, 75475

  • CHU Lyon Sud

    Pierre-Bénite, 69495

  • Hopital Metz Tessy

    Pringy, 74374

  • Hopital Robert Debre

    Reims, 51000

  • Chu Ch.Nicolle

    Rouen, 76031

  • Service: CHU saint-etienne

    Saint Priez En Jarez, 42270

  • Centre Hospitalier Universitaire

    Strasbourg, 67098

  • CHU Rangueil

    Toulouse, 31059

  • Hopital Purpan

    Toulouse, 31059

  • CHU Nancy

    Vandœuvre-lès-Nancy, 54511

  • Groupe hospitalier mutualiste les portes du Sud

    Vénissieux, 69694

Other trials in France

Germany25 sites
  • Gemeinschaftspraxis im MEDICUM

    Altenholz, 24161

  • Gastroenterologische Praxis Dr. med. B. Adami

    Alzey, 55232

  • Studienzentrum Aschaffenburg

    Aschaffenburg, 63739

  • Gastroenterologie Am Bayerischen Platz

    Berlin, 10825

  • Kreiskliniken Altotting-Burghausen

    Burghausen, 84489

  • Interdisciplinaeres Crohn-Colitis Centrum Rhein-Main

    Frankfurt am Main, 60594

  • Gemeinschaftspraxis Dr. R Denger und Dr. T. Pfitzner

    Friedrichsthal, 66299

  • PraxisZentrum fuer Gastroenterologie

    Grevenbroich, 41515

  • Hamburgisches Forschungsinstitut fur chronisch entzuendliche

    Hamburg, 20148

  • Gastroenterologische Gemeinschaftspraxis Herne

    Herne, 44623

  • Internisten am Markt Dres. Schwerdtfeger & Lehmann

    Köthen, 06366

  • Internistische Gemeinschaftspraxis fuer Verdauungs- und Stoffwechselerkrankungen

    Leipzig, 04229

  • Onco Studies an der Onkologie Dreiländereck

    Loerrach, 79539

  • St. Marienkrankenhaus

    Ludwigshafen am Rhein, Gartenstadt, 67076

  • Universitaetsmedizin Mannheim

    Mannheim, 68135

  • Magen-Darm Praxis Prof. Dr. Krammer & Kollegen

    Mannheim, 68165

  • Gastroenterologische Gemeinschaftspraxis Minden

    Minden, 32423

  • Praxis Prof.Dr. med. Herbert Kellner

    Muenchen-Nymphenburg, 80639

  • Medizinisches Versorgungszentrum Portal 10

    Münster, 48155

  • Gastroenterologische Gemeinschaftspraxis am Germania-Campus

    Münster, 48159

  • Praxiszentrum Alte Maelzerei

    Regensburg, 93053

  • Magen-Darm-Zentrum Remscheid

    Remscheid, 42859

  • Zentrum für Gastroenterologie Saarbrücken MVZ GmbH

    Saarbrücken, 66111

  • Ambulanzzentrum-Schweinfurt

    Schweinfurt, 97421

  • Gastroenterologische Schwerpunktpraxis Stuttgart

    Stuttgart, 70178

Other trials in Germany

Italy23 sites
  • Fondazione Poliambulanza - Istituto Ospedaliero

    Brescia, 25124

  • Azienda Ospedaliera per l'Emergenza Cannizzaro

    Catania, 95100

  • Azienda Ospedaliero Universitaria - Policlinico "Vittorio Emanuele"

    Catania, 95123

  • Università degli Studi "G. d'Annunzio" Chieti - Pescara

    Chieti, 66100

  • ASL 11 Empoli - Ospedale San Giuseppe

    Empoli, FI, 50053

  • ASUR Area Vasta n. 4 - Ospedale A. Murri

    Fermo, 63900

  • Azienda Ospedaliero Universitaria Careggi

    Florence, FI, 50134

  • Azienda Ospedaliera Universitaria Careggi

    Florence, 50134

  • Università degli Studi di Genova

    Genova, 16132

  • A.O.U. Policlinico "G.Martino"

    Messina, 98125

  • Azienda Ospedaliera - Universitaria di Modena Policlinico

    Modena, 41124

  • Ospedale "Sacro Cuore - Don Calabria"

    Negrar, Verona, 27024

  • Azienda Ospedaliero Universitaria Policlinico Paolo Giaccone

    Palermo, 90127

  • Az.Osp. Ospedali Riuniti 'Villa Sofia-Cervello

    Palermo, 90146

  • Azienda Ospedaliero-Universitaria di Parma

    Parma, PR, 43126

  • AOUP - Ospedale di Cisanello

    Pisa, 56124

  • Azienda Ospedaliera Universitaria di PISA

    Pisa, 56124

  • Ospedale Generale Provinciale di Macerata

    Province of Macerata, 62100

  • Ospedale Sandro Pertini

    Roma, 00157

  • Ospedale San Camillo

    Rome, 00152

  • Presidio Ospedaliero "M. Raimondi"

    San Cataldo (Caltanisetta), Caltanisetta, 93100

  • I.R.C.C.S. Policlinico San Donato

    San Donato Milanese, Milano, 20097

  • A.O.U. "S. Maria della Misericordia di Udine"

    Udine, 33100

Other trials in Italy

Spain23 sites
  • Hospital de Alcorcon

    Alcorcón, Madrid, 28922

  • Hospital Universitari Germans Trias i Pujol

    Badalona, Barcelona, 08916

  • Hospital Arquitecto Marcide

    Ferrol, A Coruna, 15405

  • Hospital Universitario de Fuenlabrada

    Fuenlabrada, Madrid, 28942

  • Hospital Universitari de Girona Dr. Josep Trueta

    Girona, Barcelona, 17007

  • Hospital Universitario de Gran Canaria DR NEGRIN

    Las Palmas de Gran Canari, Canary Islands, 35010

  • Hospital Universitario La Princesa

    Madrid, 28006

  • Hospital Universitario Gregorio Marañon

    Madrid, 28007

  • Hospital Ramon y Cajal

    Madrid, 28034

  • Hospital Clinico San Carlos

    Madrid, 28040

  • Hospital Fundación Jiménez Díaz

    Madrid, 28040

  • Hospital Universitario La Paz

    Madrid, 28046

  • Hospital Son Espases

    Palma. Mallorca, Balearic Islands, 07120

  • Complejo Hospitalario de Navarra

    Pamplona, Navarre, 31008

  • Hospital Alvaro Cunqueiro

    Pontevedra, 36312

  • Hospital de Sabadell

    Sabadell, Barcelona, 08208

  • Hospital Universitario Infanta Sofia

    San Sebastian de Los Reye, Madrid, 28702

  • Hospital Clinico Universitario de Santiago

    Santiago de Compostela, A Coruna, 15706

  • Hospital de Galdakao

    Usansolo, Bizkaia, 48960

  • Hospital Clínico de Valencia

    Valencia, 46010

  • Consorci Hospital General Universitari de Valencia

    Valencia, 46014

  • Hospital Universitari i Politecnic La Fe

    Valencia, 46026

  • Hospital Clinico Universitario de Valladolid

    Valladolid, 47005

Other trials in Spain

United Kingdom10 sites
  • Heart of England NHS Foundation Trust

    Birmingham, B9 5SS

  • The Royal Bournemouth Hospital

    Bournemouth, BH7 7DW

  • University Hospital Coventry

    Coventry, WEST Midlands, CV2 2DX

  • Dorset County Hospital

    Dorchester, Dorset, DT1 2JY

  • Royal Gwent Hospital

    Exeter, Devon, EX2 5DW

  • Gloucestershire Hospitals - NHS Foundation Trust

    Gloucester, Gloucestershire, GL1 3NN

  • Queen Alexandra Hospital

    Hampshire, PO6 3LY

  • Cwm Taf University Health Board

    Llantrisant, Wales, CF72 8XR

  • Salisbury NHS Foundation Trust

    Salisbury, Wiltshire, SP2 8BJ

  • Southampton General Hospital

    Southampton, SO16 6YD

Other trials in United Kingdom

Greece7 sites
  • Hippokration General Hospital of Athens

    Athens, Attica, 11527

  • Evangelismos Hospital

    Athens, 10676

  • Venizeleio Hospital of Heraklion

    Heraklion, Crete, 71409

  • University Hospital of Ioannina

    Ioannina, 455 00

  • University Hospital of Larissa

    Larissa, 41110

  • University Hospital of Patras

    Rio, Patra, Achaia, 265 04

  • General Hospital of Thessaloniki Ippokrateio

    Thessaloniki, 54642

Other trials in Greece

Czechia5 sites
  • Fakultni Nemocnice Hradec Kralove

    Hradec Králové, 500 05

  • Hradecká Poliklinika III, HEPATO-GASTROENTEROLOGIE HK, s.r.o

    Hradec Králové, 500 12

  • Centrum péce o zažívací trakt, Vítkovická nemocnice

    Ostrava - Vitkovice, 703 84

  • IKEM (Institut Klinické a Experimentální Medicíny)

    Prague, 140 21

  • Nemocnice Na Bulovce

    Praha 8 Liben, 180 81

Other trials in Czechia

Portugal4 sites
  • Hospital Prof. Doutor Fernando Fonseca E.P.E

    Amadora, Lisbon District, 2720-276

  • Centro Hospitalar Barreiro Montijo, E.P.E

    Barreiro, 2830-003

  • Centro Hospitalar Lisboa Norte, E.P.E.- Hospital Santa Maria

    Lisbon, 1649-035

  • Centro Hospitalar entre Douro e Vouga E.P.E.

    Santa Maria Da Feira, Porto District, 4520-211

Other trials in Portugal

Finland3 sites
  • Keski-Suomen keskussairaala

    Jyväskylä, FI-40620

  • Oulu University Hospital

    Oulu, 90220

  • Turku University Hospital

    Turku, 20521

Other trials in Finland

Hungary3 sites
  • Semmelweis University

    Budapest, H-1088

  • MH Egeszsegugyi Kozpont - Honvedkorhaz

    Budapest, H-1134

  • Szte szent-gyorgyi albert klinikai kozpont

    Szeged, H-6725

Other trials in Hungary

Netherlands3 sites
  • Ziekenhuis Gelderse Vallei

    Ede, 6716 RP

  • Catharina Ziekenhuis

    Eindhoven, 5623

  • Rijnstate

    Gelderland, 6815 AD

Other trials in Netherlands

Belgium2 sites
  • UZ Antwerpen

    Edegem, 2650

  • UZ Leuven Campus Gasthuisberg

    Leuven, Vlaams Brabant, 3000

Other trials in Belgium

Slovakia2 sites
  • FNsP F. D. Roosevelta Banska Bystrica

    Banská Bystrica, 974 01

  • V. interna klinika LFUK a UNB, Ambulancia pre nespecificke zapalove ochorenia

    Bratislava, 826 06

Other trials in Slovakia

About this study

Official title: POST-MARKETING OBSERVATIONAL COHORT STUDY OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE (IBD) TREATED WITH CT-P13 IN USUAL CLINICAL PRACTICE (CONNECT-IBD)

This is a post-marketing observational study of patients with Inflammatory Bowel Disease (specifically, Crohn's disease or Ulcerative Colitis) who have been prescribed CT-P13 (infliximab) or Remicade (infliximab) for treatment. CT-P13 (brand names Inflectra and Remsima) is a biosimilar medicine to Remicade, meaning it is a biologic medicine that contains the same active substance as Remicade (infliximab). The key study objectives are as follows:

  • To characterize the population and drug utilization patterns of patients treated with CT-P13 for Crohn's Disease (CD) or Ulcerative Colitis (UC) in the context of standard of care Remicade
  • To explore the long-term safety profile of CT-P13 in the treatment of patients with CD or UC in the context of standard of care Remicade
  • To assess the effectiveness of CT-P13 in the treatment of patients with CD or UC in the context of standard of care Remicade
Read the detailed description

The study will be conducted in accordance with legal and regulatory requirements with scientific purpose, value and rigor following generally accepted research practices described in Guidelines for Good Pharmacoepidemiology Practices (GPP), Good Epidemiological Practice (GEP), Good Practices for Outcomes Research, International Ethical Guidelines for Epidemiological Research, European Medicines Agency (EMA) European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP) Guide on Methodological Standards in Pharmacoepidemiology, and FDA Guidance for Industry. Data sources will be validated and will consist of the hospital medical records and monitoring will be organized on a regular basis. Data for the study will be entered into a web based electronic data capture (EDC) system at enrolment and then approximately every 3 months (at a minimum) thereafter up to 2 years. Adverse events will be encoded according to MedDRA 17.1 or later. The sample size will be approximately 2500 patients recruited over a 30 month period and followed up to 2 years. No inferential analyses are planned. Statistical analysis will be descriptive in nature.

Being tested
CT-P13, Remicade
Keywords
CT-P13, Inflectra, Remicade, Infliximab, Observational, Follow-up, Safety, Effectiveness
Medical subject headings
Inflammatory Bowel Diseases, Colitis, Ulcerative, Crohn Disease

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • CT-P13Drug

    Also called Inflectra, Remsima

    biosimilar infliximab

  • RemicadeDrug

    infliximab

Study groups in NCT02539368
Study groupRoleWhat they receive
CT-P13biosimilar infliximab
Receives: Drug: CT-P13
Remicadeinfliximab
Receives: Drug: Remicade

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Disease Characteristics of Participants: Disease Duration

    Disease duration was defined as the number of months from initial diagnosis of inflammatory bowel disease (CD or UC) to the date of informed consent, which was recorded at the time of enrollment into the study (baseline).

    Measured: Baseline (Day 1)

  2. Number of Participants Who Switched Treatment

    Here, number of participants with either UC or CD, who switched from remicade to CT-P13; switched from CT-P13 to remicade and multiple switchers were reported.

    Measured: From baseline to follow-up period (up to a maximum duration of 2 years)

  3. Reasons for Switching Treatment by Participants

    Measured: From baseline to follow-up period (up to a maximum duration of 2 years)

  4. Total Dose of Infusion Received

    Total dose of infusion received by the participants was calculated.

    Measured: From baseline to follow-up period (up to a maximum duration of 2 years)

  5. Number of Participants by Frequency of Infusion Received

    Number of participants by infusion frequency (weeks) were reported at baseline and categorized as follows: once a week; once every 2 weeks; once every 3 weeks; once every 4 weeks; once every 5 weeks; once every 6 weeks; once every 7 weeks; once every 8 weeks and others. Here, 'Others' category included all the frequencies apart from the mentioned categories.

    Measured: Baseline (Day 1)

  6. Number of Participants Who Had Change in Infusion Dose

    Participants who had change in the dose of infusion (either dose reduction or increase in dose) were included and reported.

    Measured: From baseline to follow-up period (up to a maximum duration of 2 years)

  7. Number of Participants Who Had Change in Infusion Dose Categorized Based on Reasons of Change

    Participants who had change in infusion dose due to various reasons such as principal investigator's decision, participant's decisions, loss of response, lack of compliance, hypersensitivity, occurrence of adverse event (including adverse event special interest [AESI]/ serious adverse event [SAE]), positive for antibodies and other were reported. Here, 'Others' category included all reasons apart from the mentioned categories. A participant could have different reasons of dose change across visits, hence could be counted in more than one category.

    Measured: From baseline to follow-up period (up to a maximum duration of 2 years)

  8. Number of Participants Who Took Concomitant Medications Related to the Treatment of Crohn's Disease (CD) or Ulcerative Colitis (UC)

    Measured: From baseline to follow-up period (up to a maximum duration of 2 years)

  9. Number of Participants With Treatment-Emergent Adverse Event (AEs), Serious Adverse Events (SAEs) and Adverse Event With Special Interest (AESIs)

    An AE was any untoward medical occurrence in a participant who received study treatment without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death, initial or prolonged inpatient hospitalization, life-threatening experience (immediate risk of dying), persistent or significant disability or incapacity, congenital anomaly. Treatment-emergent were events between first dose of infusion up to month 24, that were absent before treatment or that worsened relative to pretreatment state. Hypersensitivity was the pre-defined TEAE of special Interest for this study. AEs included both serious and non-serious adverse events.

    Measured: From baseline to follow-up period (up to a maximum duration of 2 years)

Secondary outcomes (14)
  1. Number of Participants Remaining in Clinical Remission or Relapse

    Clinical remission in participants was defined by a total Mayo score of 2 points or lower, with no individual sub score exceeding 1 point. Mayo score is an instrument designed to measure disease activity. It consisted of 4 sub scores: stool frequency, rectal bleeding, findings of centrally read flexible proctosigmoidoscopy and physician's global assessment, each sub score graded from 0 to 3 with higher scores indicating more severe disease. These scores were summed up to give a total score range of 0 to 12; where higher scores indicating more severe disease. The relapse of clinical remission was defined as the time from the date of first attaining CR to the date of relapse or death from any cause, whichever occurred first.

    Measured: Months 6, 12, 18 and 24

  2. Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index (HBI) According to Clinical Remission

    HBI is a simple index of CD activity. HBI measures 5 parameters; the general well-being (ranging from 0=very well to 4=terrible), abdominal pain ranging from 0 (none) to 3 (severe), number of liquid stools per day (no maximum score), presence of an abdominal mass on physical exam ranging from 0 (none) to 3 (definite and tender), and whether there are any complications ranging from 0=no complications, 1=Arthralgia; 2=Uveitis; 3=Erythema nodosum; 4=Aphthous ulcer; 5=Pyoderma gangrenosum; 6=Anal fissure; 7=New fistula and 8=abscess). The total HBI score is the sum of all the 5 individual parameters, the minimum score is 0 and there was no pre-specified maximum score as it depends on the number of liquids stools. Higher HBI scores=greater disease activity. The level of disease activity was interpreted as clinical remission (CR) (score less than [<] 5), mild disease (MD) (score equal to [=] 5 to 7), moderate disease (Mod D) (score=8 to 16) and severe disease (SD) (score more than [>] 16).

    Measured: Baseline, Months 6, 12, 18 and 24

  3. Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity

    HBI is a simple index of CD activity. HBI measures 5 clinical parameters; the general well-being ranging from 0 (very well) to 4 (terrible), abdominal pain ranging from 0 (none) to 3 (severe), number of liquid stools per day (no maximum score), presence of an abdominal mass on physical exam ranging from 0 (none) to 3 (definite and tender), and whether there are any complications ranging from 0=no complications, 1=Arthralgia; 2=Uveitis; 3=Erythema nodosum; 4=Aphthous ulcer; 5=Pyoderma gangrenosum; 6=Anal fissure; 7=New fistula and 8=abscess). The total HBI score is the sum of all the 5 individual parameters, the minimum score is 0 and there was no pre-specified maximum score as it depends on the number of liquids stools. Higher HBI scores=greater disease activity. The level of disease activity was interpreted as clinical remission (CR) (HBI score < 5), mild disease (MD) (HBI score = 5 to 7), moderate disease (Mod D) (HBI score = 8 to 16) and severe disease (SD) (HBI score >16).

    Measured: Baseline, Months 6, 12, 18 and 24

  4. Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Clinical Remission

    Mayo Score is an instrument to measure disease activity of UC. Score ranges from 0 to 12 points. It consists of 4 sub scores, each graded from 0 to 3. Higher scores = more severe disease. A Partial Mayo Score (PMS) (Mayo score without endoscopy) is comprised of 3 parameters: stool frequency ranging from 0 (normal number of stools) to 3 (having >=5 stools more than normal), the presence of rectal bleeding (ranging from 0=no blood seen to 3=blood alone passes), and physician's global assessment (ranging from 0=normal to 3=severe disease). The total partial Mayo score was the sum of all the parameters, score ranging from 0 (normal or inactive disease) to 9 (severe disease). Higher scores indicated more severe disease. The score was calculated if data were available for at least 1 of 3 Mayo sub scores. The level of disease activity was interpreted as clinical remission (CR) (PMS <2), mild disease (MD) (PMS=2 to 4), moderate disease (Mod D) (PMS=5 to 6) and severe disease (SD) (PMS >6).

    Measured: Baseline, Months 6, 12, 18 and 24

  5. Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity

    Mayo Score is an instrument to measure disease activity of UC. Score ranges from 0 to 12 points. It consists of 4 sub scores, each graded from 0 to 3. Higher scores= more severe disease. A Partial Mayo Score (PMS) (Mayo score without endoscopy) is comprised of 3 parameters: stool frequency ranging from 0 (normal number of stools) to 3 (having >=5 stools more than normal), the presence of rectal bleeding ranging from 0 (no blood seen) to 3 (blood alone passes), and physician's global assessment ranging from 0 (normal) to 3 (severe disease). The total partial Mayo score was the sum of all the parameters, score ranging from 0 (normal or inactive disease) to 9 (severe disease). Higher scores indicated more severe disease. The score was calculated if data were available for at least 1 of 3 Mayo sub scores. The level of disease activity was interpreted as clinical remission (CR) (PMS <2), mild disease (MD) (PMS=2 to 4), moderate disease (Mod D) (PMS=5 to 6) and severe disease (SD) (PMS >6).

    Measured: Baseline, Months 6, 12, 18 and 24

  6. Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Age at Diagnosis

    The Montreal classification index for CD was used to classify the extent of the disease activity. It consisted of three parameters: age at diagnosis, location and behavior of the disease activity. There were four different age groups categorized: 16 years or younger, 17-40 years, over 40 years and missing.

    Measured: At Baseline

  7. Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location

    The Montreal classification index for CD was used to classify the extent of the disease activity. It consisted of three parameters: age at diagnosis, location and behavior of the disease activity. There are four different disease locations presented: Location 1 (L1) is terminal ileum, Location 2 (L2) is colon, Location 3 (L3) is ileocolon and Location 4 (L4) is upper gastrointestinal (GI). The first three categories (L1-L3) was combined with L4 where disease sites coexisted.

    Measured: Baseline, Months 6, 12, 18 and 24

  8. Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity

    The Montreal classification index for CD was used to classify the extent of the disease activity. It consists of two parameters: location and behavior of the disease activity. There were 4 different categories for the behavior of the disease activity: Behaviour 1 (B1) was nonstricturing (NS), nonpenetrating (NP); Behaviour 2 (B2) was structuring; Behaviour 3 (B3) was penetrating and p as perianal disease (p). The first 3 categories (B1 to B3) could be added with p to indicate coexisting perianal disease. Perianal disease (p) was defined as the presence of perianal abscesses or fistulae.

    Measured: Baseline, Months 6, 12, 18 and 24

  9. Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Extent

    The Montreal classification index for Ulcerative Colitis (UC) was used to classify the extent and severity of the disease activity. There were three subgroups of UC defined by extent: Extent 1 (E1) =Ulcerative proctitis, Extent 2 (E2) =Left-sided UC and Extent 3 (E3) =Extensive UC.

    Measured: Baseline, Months 6, 12, 18 and 24

  10. Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Severity

    The Montreal classification index for UC was used to classify the extent and severity of the disease activity. UC can be classified broadly into four disease activity/severity categories: Severity 0 (S0) = asymptomatic clinical remission; Severity 1 (S1) = Mild UC (passage of four or fewer stools/day [with or without blood], absence of any systemic illness, and normal inflammatory markers); Severity 2 (S2) = Moderate UC (passage of more than four stools per day but with minimal signs of systemic toxicity) and Severity 3 (S3) = Severe UC (passage of at least six bloody stools daily).

    Measured: Baseline, Months 6, 12, 18 and 24

  11. Crohn's Disease: Number of Participants Categorized on the Basis of Fistula Drainage Assessment Index

    The fistula drainage assessment index was used to assess the improvement or remission of the disease activity of Crohn's Disease, based on 6 categories: remission (remission was defined as closure of all fistulae that were draining at baseline for at least two consecutive visits); improvement (improvement defined as a decrease from baseline in the number of open draining fistulae of 50% for at least two consecutive visits); worsened; unchanged; not accessible and missing disease activity.

    Measured: Baseline, Months 6, 12, 18 and 24

  12. Mean Change From Baseline in Laboratory Test Results: C-Reactive Protein at Months 6, 12, 18, and 24

    C-reactive protein (CRP) was a laboratory measurement for evaluation of an acute phase reactant of inflammation through the use of an ultra-sensitive assay. A decrease in the level of CRP indicated reduction in inflammation and therefore improvement.

    Measured: Baseline, Months 6, 12, 18 and 24

  13. Mean Change From Baseline in Laboratory Test Results: Fecal Calprotectin at Months 6, 12, 18, and 24

    Here, the laboratory tests related to the treatment or assessment of Crohn's Disease or Ulcerative Colitis was fecal calprotectin.

    Measured: Baseline, Months 6, 12, 18, and 24

  14. Number of Participants With Imaging Test Results

    Number of participants who had Imaging test results related to the treatment or assessment of Crohn's Disease or Ulcerative Colitis were reported.

    Measured: From baseline up to follow-up period (a maximum of 2 years)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted3 Sep 2015 (estimated)
  2. Study start22 Apr 2015
  3. Primary completion31 Oct 2018
  4. Study completion31 Oct 2018

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
2,565 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02539368
Sponsor's protocol ID
ZOB INF 1402
Other IDs
C1231001
Acronym
CONNECT-IBD
Status last verified
Jan 2020
First submitted
22 Jul 2015
Last updated
13 Feb 2020
Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
No: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical\_trials/trial\_data\_and\_results/data\_requests.

Publications

  • Bokemeyer B, Hlavaty T, Allez M, Selema P, Moosavi S, Cadatal MJ, Fowler H, Mueller M, Liau KF, Gisbert JP. Real-world observational cohort study of treatment patterns and safety outcomes of infliximab biosimilar CT-P13 for the treatment of inflammatory bowel disease (CONNECT-IBD). Expert Opin Biol Ther. 2023 Jul-Dec;23(8):791-800. doi: 10.1080/14712598.2023.2200883. Epub 2023 Apr 16.

    PubMed 37038897

Questions about this trial

What is this clinical trial studying?

An observational study of Inflammatory Bowel Diseases and Ulcerative Colitis, run by Pfizer at 140 sites in 13 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 13 Feb 2020. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 140 sites in France, Germany, Italy, Spain, United Kingdom and 8 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Yes. Results are posted in the registry (first posted 13 Feb 2020). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Disease Characteristics of Participants: Disease Duration (time frame: Baseline (Day 1)). The study lists 9 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02539368, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Feb 2020.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in